Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Molecules ; 27(13)2022 Jun 21.
Artículo en Inglés | MEDLINE | ID: mdl-35807228

RESUMEN

Opioids are used to treat pain, but despite their effectiveness, they possess several side effects such as respiratory depression, tolerance and physical dependence. Cebranopadol has been evaluated as a solution to this problem. The compound acts on the mu opioid receptor and the nociceptin/orphanin receptor and these receptors co-activation can reduce opioid side-effects without compromising analgesia. In the present review, we have compiled information on the effects of cebranopadol, its pharmacokinetics, and clinical trials involving cebranopadol, to further explore its promise in pain management.


Asunto(s)
Compuestos de Espiro , Analgésicos Opioides/efectos adversos , Humanos , Indoles/farmacología , Indoles/uso terapéutico , Dolor/inducido químicamente , Dolor/tratamiento farmacológico , Compuestos de Espiro/farmacología , Compuestos de Espiro/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...